City of Hope Researchers to Share New Immunotherapy and Precision Medicine Insights Across Cancer Types at ASCO 2026

City of Hope, a leading cancer research and treatment organization in the U.S., will present 49 abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, running May 29 to June 2. The research focuses on immunotherapy and precision medicine advancements across blood cancers and solid tumors, with findings aimed at improving treatment efficacy and personalization for patients. The event highlights City of Hope’s scientific leadership, as noted by Marcel van den Brink, M.D., Ph.D., the organization’s chief physician executive. He emphasized the team’s commitment to translating research into real progress for cancer patients, with a strong emphasis on making treatments more precise and effective. Among the key presentations is Oral Abstract 7007, led by Elizabeth Budde, M.D., Ph.D., which updates efficacy and safety data from the phase 3 SUNMO study. This study compares mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The findings will include subgroup analyses for patients in second-line versus third-line plus treatments, scheduled for May 30 at 5:12 p.m. CDT. Another significant study is Rapid Oral Abstract 5014, presented by Tanya Dorff, M.D., F.A.S.C.O. This phase 1, first-in-human trial evaluates the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC). The presentation is set for May 31 at 4:42 p.m. CDT. Additionally, Rapid Oral Abstract 4519 will explore microbial dysbiosis as a predictor of benefit from CBM588 as an adjunct to immune checkpoint blockade. The full list of abstracts can be accessed on City of Hope’s official ASCO 2026 page. The presentations underscore the organization’s dedication to advancing cancer care through innovative research and collaboration with the global oncology community.